What is the bromantane dosage?

What the Russian label gives
ItemVidal label
Tablet strengths50 мг (mg) and 100 мг (mg)1
Single dose50-100 мг (mg), by mouth regardless of meals1
Dose over the day100-200 мг (mg) in 2 intakes1
Course2-4 недели (weeks), with no intake after 4 pm1

The Ladasten label, as reproduced by Vidal, gives a single dose of 50-100 мг (mg) and 100-200 мг (mg) over the day in 2 intakes;1 a 2010 study by Voznesenskaia and colleagues in 28 Russian centres, with 728 patients with asthenic disorders analysed, gave 50 to 100 mg a day for 28 days.2

What the Russian label gives

The table is set at the top of the page

Bromantane is sold in Russia as Ladasten, on prescription.31 These figures come from the Vidal copy of the label, not from the Russian register itself.

What the trials used

Three of the trials state a dose in their published summaries; the full texts were not read, and none of the summaries gives an arm-by-arm table. The multicentre study's 50 to 100 mg a day reaches only the bottom of the label's 100-200 мг (mg) a day.21

TrialDose and schedulePeopleLength
Voznesenskaia 2010, 28 centres in Russia50 to 100 mg a day2728 patients with psychoautonomic syndrome and asthenic disorders analysed (91.6% of the total sample)28 days
Reutova 2011, neurasthenia, randomisedOne 15 mg test dose of ladasten against placebo4Patients with neurasthenia, number not statedSingle dose
Bogdan 2009, laboratory studyOne 100 mg dose of ladasten5Healthy volunteers, number not statedSingle dose
Neznamov 2009, neurasthenia, randomised and blindLadasten or placebo, dose not given6Patients with neurasthenia, number not statedWash-out, then 28 days, then 1 week of placebo

Liquid, spray and powder

No label or leaflet found describes bromantane as a powder to be mixed. None gives a liquid, spray or injection concentration, and no label or human trial for a nasal spray or liquid form turned up, so no syringe mark can be tied to a source.

Safety and what is not known

The Vidal label lists pregnancy, lactation, age under 18 and hypersensitivity to the drug's components as contraindications.1 It lists possible over-activation and trouble falling asleep as central nervous system side effects, and allergic reactions where there is heightened individual sensitivity to the drug.1 The 28-centre study (Voznesenskaia 2010, 728 patients analysed) reported adverse effects in 3% of patients and discontinuation in 0.8%, and found no serious adverse effects.2 The medi.ru leaflet says a sedative effect may develop on significant overdose.7

No human dose-finding trial and no stability data were found.

Storage

The Vidal label gives tablet storage as dry, protected from light, at no more than 25 °C, with a shelf life of 2 года (years).1 The Vidal page's summary gives the storage temperature as от 2 до 25 °С (2 to 25 °C).1 The medi.ru copy gives the same.7 The labels give nothing for liquid or mixed preparations.

Frequently asked questions

Is there a US label or registered trial for bromantane?

Searches of DailyMed and ClinicalTrials.gov found no US label and no registered trial. A review says it is made in Russia as Ladasten and certified there as a drug.3

Is bromantane prohibited in sport?

The WADA 2026 Prohibited List names Bromantan among the S6.A non-specified stimulants, which are prohibited in-competition.8 A review says anti-doping rules have prohibited it since 1997.3

References

  1. Vidal (Russian drug reference reproducing the maker's label). Ладастен инструкция по применению: показания, противопоказания, побочное действие – описание Ladasten таблетки 100 мг: 50 шт. (20677) - справочник препаратов и лекарств. 2023. vidal.ru
  2. PubMed. [Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten]. 2010. pubmed.ncbi.nlm.nih.gov
  3. Biomolecules & Therapeutics. The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance. 2012. pmc.ncbi.nlm.nih.gov
  4. PubMed. [Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients]. 2011. pubmed.ncbi.nlm.nih.gov
  5. PubMed. [Effect of ladasten on the psychophysiological parameters of healthy volunteers]. 2009. pubmed.ncbi.nlm.nih.gov
  6. PubMed. [Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo)]. 2009. pubmed.ncbi.nlm.nih.gov
  7. medi.ru (Russian drug reference reproducing the maker's label). Ладастен - официальная инструкция по применению, аналоги, цена, наличие в аптеках. 2015. medi.ru
  8. WADA. WORLD ANTI-DOPING CODE. 2026. wada-ama.org